Bevacizumab in ovarian cancer [6]

首页> 外文期刊>The New England journal of medicine >Bevacizumab in ovarian cancer [6]

【24h】

Bevacizumab in ovarian cancer [6]

机译：贝伐单抗治疗卵巢癌[6]

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

dr. burger replies: The percentage of patients enrolled in GOG-0218 who received post-progression therapy with anti-vascular endothelial growth factor (VEGF) agents has yet to be determined. If a crossover effect was present, this might explain why in GOG-0218 there was no significant improvement in overall survival in the bevacizumab-throughout group despite a substantial improvement in progression-free survival. In contrast, in ICON7, in which only 3% of the patients received post-progression antiangiogen-ic therapy, a subgroup analysis involving patients with high-risk disease similar to the GOG-0218 population showed a substantial effect of bevacizumab on overall survival.

机译：博士汉堡回复：尚未确定GOG-0218中接受抗血管内皮生长因子（VEGF）治疗进行后期治疗的患者百分比。如果存在交叉效应，这可能可以解释为什么在GOG-0218中，尽管无进展生存期有显着改善，但贝伐单抗治疗组的总生存期没有显着改善。相比之下，在仅3％的患者接受进行后抗血管生成治疗的ICON7中，亚组分析涉及与GOG-0218人群相似的高危疾病患者，显示贝伐单抗对总体生存率具有实质性影响。

著录项

来源
《The New England journal of medicine》 |2012年第13期|共1页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023 [J] . Tadahiro Shoji, Shinichi Komiyama, Junzo Kigawa, BMC Cancer . 2018,第1期

机译：在铂抗性上皮卵巢卵巢卵巢卵巢卵巢卵巢，输卵管或原发性腹膜癌症患者中使用Bevacizumab用于前线或铂敏感的抗蜂巢蛋白，或没有Bevacizumab的疗效和安全性评估患者的疗效和安全性卵巢癌：日本妇科肿瘤学群体研究JGOG3023的理由，设计和方法
2. Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer? [J] . BackesF.J., RichardsonD.L., McCannG.A., International journal of gynecological cancer: official journal of the International Gynecological Cancer Society . 2013,第5期

机译：贝伐单抗在复发性卵巢癌中进展后应继续使用贝伐单抗吗？
3. Interview with Professor Uwe Wagner: Bevacizumab - New standard option in advanced ovarian cancer [Interview mit Professor Uwe Wagner: Bevacizumab - Neue Standardoption beim fortgeschrittenen Ovarialkarzinom] [J] . PohlmannB.-K. Onkologie . 2013,第11期

机译：Uwe Wagner教授访谈：贝伐单抗-晚期卵巢癌的新标准选择[Uwe Wagner教授访谈：贝伐单抗-晚期卵巢癌的新标准选择
4. Applying Quantitative Adiposity Feature Analysis Models to Predict Benefit of Bevacizumab-based Chemotherapy in Ovarian Cancer Patients [C] . Yunzhi Wang, Yuchen Qiu, Theresa Thai, Conference on medical imaging . 2016

机译：应用定量肥胖特征分析模型预测基于贝伐单抗的卵巢癌化疗获益
5. Ovarian Cancer Metabolism: Effect of Anoikis Condition and Nitric Oxide on Ovarian Cancer Metabolism, and Effect of Metabolites on Ovarian Cancer Migration [D] . Caneba, Christine Ann. 2013

机译：卵巢癌代谢：厌食症和一氧化氮对卵巢癌代谢的影响，以及代谢产物对卵巢癌迁移的影响
6. An open-label randomized phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian fallopian tube or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale design and methods of the Japanese Gynecologic Oncology Group study JGOG3023 [O] . Tadahiro Shoji, Shinichi Komiyama, Junzo Kigawa, 2018

机译：一项开放性随机II期临床试验评估接受或不接受贝伐单抗治疗的标准治疗在铂耐药的上皮性卵巢癌输卵管或原发性腹膜癌患者中接受过贝伐单抗治疗的一线或铂类敏感性的疗效和安全性卵巢癌：日本妇科肿瘤小组研究JGOG3023的原理设计和方法
7. An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023 [O] . Tadahiro Shoji, Shinichi Komiyama, Junzo Kigawa, 2018

机译：在铂抗性上皮卵巢卵巢卵巢卵巢卵巢卵巢，输卵管或原发性腹膜癌症患者中使用Bevacizumab用于前线或铂敏感的抗蜂巢蛋白，或没有Bevacizumab的疗效和安全性评估患者的疗效和安全性卵巢癌：日本妇科肿瘤学群体研究JGOG3023的理由，设计和方法

Bevacizumab in ovarian cancer [6]

摘要

著录项

相似文献

相关主题

期刊订阅